ÈÕ±¾Åú×¼LEQEMBI?¾²Âö×¢ÉäÒº£¨ÂØ¿¨Ä¹£©ÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡Ðû²¼  £¬ÈËÔ´»¯¿¹¿ÉÈÜÐÔ¾Û¼¯µí·ÛÑùÂÑ°×-¦Â (A¦Â)µ¥¿Ë¡¿¹Ìå “LEQEMBI? ¾²Âö×¢É䣨ÂØ¿¨Ä¹£º200 mg ¾²Âö×¢ÉäÓÃÒ©ºÍ Leqembi 500 mg ¾²Âö×¢ÉäÓÃÒ©£©ÔÚÈÕ±¾»ñÅú  £¬ÓÃÓÚÑÓ»º°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­£¨MCI£©ºÍÇá¶È³Õ´ôÖ¢µÄ½øÕ¹¡£

LEQEMBIÊÇÒ»ÖÖÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ìå  £¬Õë¶Ô¾Û¼¯µÄ¿ÉÈÜÐÔ£¨Ô­ÏËά*£©ºÍ²»ÐÐÈÜÐÔÐÎʽµÄ¦Âµí·ÛÑùÂÑ°×£¨A¦Â£©¡£LEQEMBIÕë¶Ô²¢Çå³ýÁ¬Ðø»ýÀÛµÄ×î¾ßÉñ¾­¶¾ÐÔµÄA¦ÂÐÎʽ  £¬²¢Çå³ýÏÖÓа߿é  £¬ÒÔÖÎÁÆÕâÖÖ½¥½øµÄÂýÐÔ¼²²¡¡£¼Ì 2023 Äê 7 ÔÂÔÚÃÀ¹ú»ñµÃ´«Í³Åú×¼Ö®ºó  £¬ÈÕ±¾Êǵڶþ¸ö»ñµÃÅú×¼µÄ¹ú¼Ò¡£

LEQEMBIµÄ´«Í³Åú×¼ÊÇ»ùÓÚÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄ´óÐÍÈ«ÇòClarity ADÁÙ´²ÊÔÑéµÄIIIÆÚÊý¾Ý¡£ÔÚ¸ÃÊÔÑéÖÐ  £¬LEQEMBIµ½´ïÁËÆäÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖÕµãµÄͳ¼ÆѧÒâÒåÉϵĽá¹û  £¬²¢Ö¤ÊµÁËLEQEMBIµÄÁÙ´²»ñÒæ¡£Ö÷ÒªÖÕµãÊÇÈ«ÇòÈÏÖªºÍ¹¦Ð§Á¿±í  £¬¼´ÁÙ´²³Õ´ôÖ¢ÆÀ·Ö×Ü±í£¨CDR-SB£©¡£Óëο½å¼ÁÏà±È  £¬LEQEMBIÖÎÁÆÔÚ18¸öÔÂʱ¼õÉÙÁËCDR-SBµÄÁÙ´²Ï½µ27%¡£´ËÍâ  £¬ÓÉAD¿´»¤ÕßÆÀ¹ÀµÄ´ÎÒªÖյ㰢¶û´Äº£Ä¬²¡Ð­×÷Ñо¿×é-Çá¶ÈÈÏÖªÕÏ°­-ÈÕ³£Éú»îÄÜÁ¦Á¿±íÆÀ·Ö£¨ADCS MCI-ADL£©ÏÔʾ³ö37%µÄÏÔÖøͳ¼Æѧ»ñÒæ¡£ÕâºâÁ¿µÄÊÇ»¼Õ߶ÀÁ¢ÔË×÷µÄÄÜÁ¦  £¬°üÂÞÄܹ»´©Ò¡¢Î¹Ê³ºÍ¼ÓÈëÉçÇø»î¶¯¡£Clarity ADÑо¿µÄÈ«²¿½á¹ûÔÚ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏÐû²¼  £¬²¢Í¬Ê±·¢±íÔÚ2022Äê11ÔÂ29ÈÕµÄͬÐÐÆÀÉóҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ê×ϯִÐйÙÄÚÌÙÇç·òÌåÏÖ  £¬¡°½ñÌì  £¬LEQEMBI »ñµÃÅú×¼  £¬³ÉΪÈÕ±¾Ê׸ö»ñÅúµÄ¿¹µí·ÛÑùÂÑ°×°¢¶û´Äº£Ä¬²¡ÖÎÁÆÒ©Îï¡£¸ÃÒ©ÎïÔÚ°¢¶û´Äº£Ä¬²¡µÄÔçÆÚºÍÇá¶È³Õ´ô½×¶Î¿É½µµÍ¼²²¡½øÕ¹ËÙ¶È  £¬¼õ»ºÈÏÖª¹¦Ð§Ë𺦡£ÎÒÃÇÏàÐÅ  £¬ÎÒÃÇÒѾ­ÏÆ¿ªÁË°¢¶û´Äº£Ä¬²¡ÖÎÁÆÊ·ÉÏеÄÒ»Ò³¡£°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖ½¥½øÐÔµÄÑÏÖؼ²²¡  £¬²»½ö»á¶Ô»¼Õß¼°Æ令Àí»ï°éÔì³ÉÑÏÖØË𺦺͸ºµ£  £¬»¹»á¶ÔÕû¸öÉç»á·¢Éú¾Þ´óÓ°Ïì  £¬×ÔÎÒÃÇÔÚÖþ²¨Ñо¿ÊÒ¿ªÊ¼³Õ´ôÖ¢Ñо¿ÒÔÀ´Ô¼ 40 Äê¼ä  £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ò»Ö±Óë³Õ´ôÖ¢»¼Õß¼°Æ令Àí»ï°é±£³Ö»¥¶¯  £¬²¢Å¬Á¦Á˽âËûÃǵÄÕæÇиÐÊÜ¡£Îª´Ë  £¬ÎÒÃDz»Í£ÌôÕ½  £¬¿ª·¢Äܹ»´Ó»ù´¡ÉϽâ¾ö°¢¶û´Äº£Ä¬²¡²¡ÀíÎÊÌâµÄÖÎÁÆÒ©Îï¡£ÎÒÃÇÖÂÁ¦ÓÚ½« LEQEMBI ×÷ΪÏû³ý²¡ÒòµÄÐÂÁÆ·¨  £¬ÌṩӦÓÐÐèÒªµÄÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼Õß¼°Æä¼ÒÊô¡£Í¨¹ýÕâЩŬÁ¦  £¬ÎÒÃǵÄÄ¿±êÊǶÔÈÕ±¾Éç»áÖÐΧÈƳմôÖ¢µÄÎÊÌâ·¢Éú»ý¼«Ó°Ï씡£

²³½¡×ܲüæÊ×ϯִÐйÙChristopher A. ViehbacherÌåÏÖ£º”»ñµÃÅú×¼ºó  £¬ÎÒÃǽ«ÄÜÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ò»Æð×ÊÖú½â¾ö°¢¶û´Äº£Ä¬²¡¶Ô»¼ÕßÔì³ÉµÄÆÆ»µÐÔÓ°Ïì  £¬ÒÔ¼°¸ø»¤Àí»ï°é´øÀ´µÄÇé¸Ð¡¢Éç»áºÍ¾­¼Ã¸ºµ£¡£ÕâÊDz³½¡ºÍÀ´Àû¹ú¼Êw66¹Ù·½ÍøվΪ¿ª´´ÖÎÁÆÕâÖÖÓ°ÏìÊý°ÙÍòÈ˵ļ²²¡µÄÐÂʱ´ú¶øÂõ³öµÄÖØÒªÒ»²½¡£ÎÒÃÇÆÚ´ýÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøվЯÊÖºÏ×÷  £¬ÔÚÃÀ¹úºÍÈÕ±¾»ñÅúµÄ»ù´¡ÉÏÔÙ½ÓÔÙÀ÷  £¬ÎªÈ«Çò»¼Õß¼°Æä¼ÒÍ¥´øÀ´ÕâһѡÔñ¡£¡°

ƾ¾ÝºñÉúÀͶ¯Ê¡¹æ¶¨µÄÅú×¼Ìõ¼þ  £¬ÔÚÉÏÊкó»ýÀÛÒ»¶¨ÊýÁ¿µÄ»¼ÕßÊý¾Ý֮ǰ  £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«¶ÔËùÓÐʹÓà LEQEMBI µÄ»¼Õß½øÐÐÉÏÊкóÌØÊâÓÃ;½á¹ûÊӲ죨ȫ²¡Àý¼à²â£©¡£´ËÍâ  £¬»¹½«Æ¾¾Ý°üװ˵Ã÷ÊéºÏÀíÍƹãʹÓà LEQEMBI  £¬²¢ÎªÒ½ÁƱ£½¡×¨ÒµÈËÔ±±àдÅàѵÖÊÁÏ  £¬ÒÔЭÖú¹ÜÀíºÍ¼à²âµí·ÛÑùÂÑ°×Ïà¹Ø³ÉÏñÒì³££¨ARIA£©¡£

LEQEMBIµÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼  £¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖÐ  £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£ÔÚÈÕ±¾  £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÈÕ±¾½«ÅäºÏÍƹã LEQEMBI  £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«×÷ΪӪÏúÊÚȨ³ÖÓÐÈË·ÖÏú¸Ã²úÎï¡£

 

Media Contacts:
Eisai
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com

 

Biogen Inc.
Jack Cox
+ 1 781-464-3260
public.affairs@biogen.com

 

Investor Contacts:?
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122

 

Biogen Inc.
Chuck Triano
+ 1-781-464-2442
IR@biogen.com